Meeting
2020 ASCO Virtual Scientific Program
Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation.
Authors
Josiah An
University of Iowa Hospitals and Clinics, Iowa City, IA
Josiah An , Melissa Yan , Nanmeng Yu , Adithya Chennamadhavuni , Muhammad Furqan , Timothy Kruser , Timothy L Sita , Ryan Nguyen , Lawrence Eric Feldman , Mary Pasquinelli , Nasser H. Hanna , Taher Abu Hejleh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9033)
DOI
10.1200/JCO.2020.38.15_suppl.9033
Abstract #
9033
Poster Bd #
226
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Molecular characterization of resistance to immune checkpoint inhibitor and chemotherapy treatment in advanced non-small cell lung cancer.
First Author: Jordan Kardos
Poster
2024 ASCO Annual Meeting
PD-L1 expression in pulmonary sarcomatoid carcinoma and response to immunotherapy.
First Author: Lingzhi Hong
Poster
2023 ASCO Annual Meeting
Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.
First Author: Charu Aggarwal
Poster
2023 ASCO Annual Meeting
The genomic, transcriptomic, and immunological landscape of SGLT2 in lung cancer.
First Author: Heng Tan